The hunt for biomarkers for patients with hepatocellular carcinoma (HCC) or liver cancer ensues as an explosion of novel agents, either approved or in the clinical trials pipeline, opens the door for tremendous opportunity to develop heretofore not possible treatments for this dangerous cancer.
Recently, OncLive profiled the Imperial College of London’s David J. Pinato, MD, PhD, a prominent Clinical Scientists and Consultant Medial Oncologist supported by the Wellcome Trust Strategic Fund (IPPRF scheme) working in the Department of Surgery and Cancer. He and other well-known investigators form around elite oncology research hubs as teams on the hunt for optimal biomarkers that could predict response to the growing number of HCC therapies. Targets include PD-L1 expression for immunotherapy in addition to FGF19 expression. Moreover, as treatment technology advances along with intensified biomarker research in the future researchers may be able to identify the best treatment based on the underlying molecular structure of the liver cancer tumor.
The OncLive Interview
During the recent 2020 HCC-TAG Conference, OncLive got in front of Dr. Pinato for a discussion about the clinical and biological challenges in identifying biomarkers in HCC and how these new findings can influence research utilizing the new ongoing findings across major research centers.
Call to Action: interested in these details? We recommend you read the full interview at OncLive.